Targeting the tumor microenvironment of Ewing sarcoma

被引:7
|
作者
Morales, Erin [1 ]
Olson, Michael [2 ,3 ]
Iglesias, Fiorella [4 ]
Luetkens, Tim [5 ,6 ,7 ]
Atanackovic, Djordje [5 ,6 ,7 ]
机构
[1] Univ Utah, Pediat Hematol Oncol Dept, Salt Lake City, UT 84132 USA
[2] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA
[3] Univ Utah, Huntsman Canc Inst, Hematol & Hematol Malignancies, Salt Lake City, UT 84112 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA
[5] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[6] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[7] Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA
关键词
cancer vaccines; CAR T cells; chemokines; cytokines; Ewing sarcoma; immune checkpoint inhibition; immune escape; immunosuppression; immunotherapy; microenvironment; monoclonal antibodies; T cells; TCR-transduced T cells; tumor immunology; tumor microenvironment; REGULATORY T-CELLS; MYELOID SUPPRESSOR-CELLS; EMERGING EFFECTOR-CELLS; NITRIC-OXIDE SYNTHASE; CIRCULATING FIBROCYTES; REACTIVE OXYGEN; ANTITUMOR-ACTIVITY; PERIPHERAL-BLOOD; IMMUNE CELLS; II RECEPTOR;
D O I
10.2217/imt-2020-0341
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lay abstract Ewing sarcoma is an aggressive type of cancer of the bones or soft tissues that mainly affects teenagers. Patients are often treated with intensive treatments which may include chemotherapy in combination with radiation and/or surgery. For patients who present with cancer that has already spread to other sites or that returns after treatment, the cancer can be very hard to cure. This leads to the need for different therapies. Therapies that use the help of the immune system to combat the cancer, called immunotherapies, have had limited success, which is thought to be due to factors in the environment of the tumor that weaken the immune system and so dampen any potential use of it to destroy the cancer cells. We provide an overview of these factors in the tumor environment that allow the cancer cells to escape the immune system; we also discuss potential options to target these factors and, in this way, allow the immunotherapies to destroy the cancer cells more effectively. Ewing sarcoma is an aggressive tumor type with an age peak in adolescence. Despite the use of dose-intensified chemotherapy as well as radiation and surgery for local control, patients with upfront metastatic disease or relapsed disease have a dismal prognosis, highlighting the need for additional therapeutic options. Different types of immunotherapies have been investigated with only very limited clinical success, which may be due to the presence of immunosuppressive factors in the tumor microenvironment. Here we provide an overview on different factors contributing to Ewing sarcoma immune escape. We demonstrate ways to target these factors in order to make current and future immunotherapies more effective and achieve deeper and more durable responses in patients with Ewing sarcoma.
引用
收藏
页码:1439 / 1451
页数:13
相关论文
共 50 条
  • [41] Nanotheranostics Targeting the Tumor Microenvironment
    Roma-Rodrigues, Catarina
    Pombo, Ines
    Raposo, Luis
    Pedrosa, Pedro
    Fernandes, Alexandra R.
    Baptista, Pedro, V
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2019, 7 (AUG):
  • [42] Targeting Angiogenesis and the Tumor Microenvironment
    Samples, Jennifer
    Willis, Monte
    Klauber-DeMore, Nancy
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 22 (04) : 629 - +
  • [43] Nanotherapy Targeting the Tumor Microenvironment
    Gong, Bo-Shen
    Wang, Rui
    Xu, Hong-Xia
    Miao, Ming-Yong
    Yao, Zhen-Zhen
    CURRENT CANCER DRUG TARGETS, 2019, 19 (07) : 525 - 533
  • [44] Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma
    Yeung, Choh
    Gibson, Anna E.
    Issaq, Sameer H.
    Oshima, Nobu
    Baumgart, Joshua T.
    Edessa, Leah D.
    Rai, Ganesha
    Urban, Daniel J.
    Johnson, Michelle S.
    Benavides, Gloria A.
    Squadrito, Giuseppe L.
    Yohe, Marielle E.
    Lei, Haiyan
    Eldridge, Sandy
    Hamre, John, III
    Dowdy, Tyrone
    Ruiz-Rodado, Victor
    Lita, Adrian
    Mendoza, Arnulfo
    Shern, Jack F.
    Larion, Mioara
    Helman, Lee J.
    Stott, Gordon M.
    Krishna, Murali C.
    Hall, Matthew D.
    Darley-Usmar, Victor
    Neckers, Leonard M.
    Heske, Christine M.
    CANCER RESEARCH, 2019, 79 (19) : 5060 - 5073
  • [45] Targeting Immunotherapy to the Tumor Microenvironment
    Dougan, Michael
    Dougan, Stephanie K.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2017, 118 (10) : 3049 - 3054
  • [46] Nanoconstructs for targeting the tumor microenvironment
    Vannucci, Luca
    Rajsiglova, Lenka
    Stakheev, Dmitry
    Ceez, Pierpaolo
    Falvo, Elisabeua
    Babic, Michel
    Kostiv, Uliana
    Caja, Fabian
    Krizan, Sri
    Vrba, Jan
    Vrba, Jan, Jr.
    Vrba, David
    Farina, Laura
    Lopresto, Venni
    Ruvio, Giuseppe
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S41 - S41
  • [47] Therapeutic Targeting of the Tumor Microenvironment
    Bejarano, Leire
    Jordao, Marta J. C.
    Joyce, Johanna A.
    CANCER DISCOVERY, 2021, 11 (04) : 933 - 959
  • [48] Nanomedicines Targeting the Tumor Microenvironment
    Tong, Rong
    Langer, Robert
    CANCER JOURNAL, 2015, 21 (04): : 314 - 321
  • [49] Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy
    Luo, Wen
    Hoang, Hai
    Zhu, Hongwen
    Miller, Katherine
    Mo, Xiaokui
    Eguchi, Shiori
    Tian, Meijuan
    Liao, Yanling
    Ayello, Janet
    Rosenblum, Jeremy M.
    Marcondes, Mario
    Currier, Mark
    Mardis, Elaine
    Cripe, Timothy
    Lee, Dean
    Cairo, Mitchell S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
  • [50] Ewing Sarcoma and Ewing-Like Sarcoma
    Yoshida, Akihiko
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S9 - S10